# Sensus Healthcare, Inc.: overview SRTS · Nasdaq · CIK 1494891 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/srts.md) · [Financials](/companies/srts/financials.md) · [Filings](/companies/srts/filings.md) · [Insiders](/companies/srts/insiders.md) Latest reported revenue: [$2.3m](/filings/0001753926-26-001508.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001753926-26-001508). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [8.8](/filings/0001753926-25-001745.md) | [13.1 d](/filings/0001753926-26-000435.md) | [8.3](/filings/0001753926-25-000853.md) | [7.3](/filings/0001753926-25-001290.md) | [6.9](/filings/0001753926-25-001745.md) | [4.9 d](/filings/0001753926-26-000435.md) | [3.4](/filings/0001753926-26-000845.md) | [2.3](/filings/0001753926-26-001508.md) | | Gross margin | % | [59.3%](/filings/0001753926-25-001745.md) | [54.4% d](/filings/0001753926-26-000435.md) | [52.2%](/filings/0001753926-26-000845.md) | [39.7%](/filings/0001753926-26-001508.md) | [39.4%](/filings/0001753926-25-001745.md) | [38.4% d](/filings/0001753926-26-000435.md) | [29.2%](/filings/0001753926-26-000845.md) | [33.6%](/filings/0001753926-26-001508.md) | | Operating margin | % | [16.9%](/filings/0001753926-25-001745.md) | [13.2% d](/filings/0001753926-26-000435.md) | [(31.7%)](/filings/0001753926-26-000845.md) | [(26.6%)](/filings/0001753926-26-001508.md) | [(37.3%)](/filings/0001753926-25-001745.md) | [(63.7%) d](/filings/0001753926-26-000435.md) | [(128.4%)](/filings/0001753926-26-000845.md) | [(138.9%)](/filings/0001753926-26-001508.md) | | Net margin | % | [13.7%](/filings/0001753926-25-001745.md) | [11.8% d](/filings/0001753926-26-000435.md) | [(30.8%)](/filings/0001753926-26-001508.md) | [(14.2%)](/filings/0001753926-26-001508.md) | [(13.7%)](/filings/0001753926-25-001745.md) | [(64.1%) d](/filings/0001753926-26-000435.md) | [(77.4%)](/filings/0001753926-26-001508.md) | [(382.1%)](/filings/0001753926-26-001508.md) | | Diluted EPS | $ per share | [0.07](/filings/0001753926-25-001745.md) | not reported | [(0.16)](/filings/0001753926-26-000845.md) | [(0.06)](/filings/0001753926-26-001508.md) | [(0.06)](/filings/0001753926-25-001745.md) | not reported | [(0.16)](/filings/0001753926-26-000845.md) | [(0.53)](/filings/0001753926-26-001508.md) | | Free cash flow | $m | [3.6 d](/filings/0001753926-25-001745.md) | [(1.1) d](/filings/0001753926-26-000435.md) | [(2.7)](/filings/0001753926-26-000845.md) | [3.1 d](/filings/0001753926-26-001508.md) | [2.3 d](/filings/0001753926-25-001745.md) | [(2.4) d](/filings/0001753926-26-000435.md) | [(3.8)](/filings/0001753926-26-000845.md) | [(3.1) d](/filings/0001753926-26-001508.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [27.0](/filings/0001213900-23-022355.md) | [44.5](/filings/0001213900-24-023093.md) | [24.4](/filings/0001753926-25-000408.md) | [41.8](/filings/0001753926-26-000435.md) | [27.5](/filings/0001753926-26-000435.md) | | Gross margin | % | [62.8%](/filings/0001213900-23-022355.md) | [66.5%](/filings/0001213900-24-023093.md) | [57.6%](/filings/0001753926-25-000408.md) | [58.4%](/filings/0001753926-26-000435.md) | [43.2%](/filings/0001753926-26-000435.md) | | Operating margin | % | [15.2%](/filings/0001213900-23-022355.md) | [33.3%](/filings/0001213900-24-023093.md) | [(1.6%)](/filings/0001753926-25-000408.md) | [19.4%](/filings/0001753926-26-000435.md) | [(37.5%)](/filings/0001753926-26-000435.md) | | Net margin | % | [15.2%](/filings/0001213900-23-022355.md) | [54.4%](/filings/0001213900-24-023093.md) | [2.0%](/filings/0001753926-25-000408.md) | [15.9%](/filings/0001753926-26-000435.md) | [(28.1%)](/filings/0001753926-26-000435.md) | | Diluted EPS | $ per share | [0.25](/filings/0001213900-23-022355.md) | [1.46](/filings/0001213900-24-023093.md) | [0.03](/filings/0001753926-25-000408.md) | [0.41](/filings/0001753926-26-000435.md) | [(0.47)](/filings/0001753926-26-000435.md) | | Free cash flow | $m | [(0.4)](/filings/0001213900-23-022355.md) | [(1.6)](/filings/0001213900-24-023093.md) | [(2.4)](/filings/0001753926-25-000408.md) | [(1.1)](/filings/0001753926-26-000435.md) | [0.3](/filings/0001753926-26-000435.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/srts/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Pacific Ridge Capital Partners, LLC](/funds/1591546.md) | 2026-06-30 | $2.4m | 789,675 | | Reduced −6,397 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.0m | 660,402 | | Added +12,177 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $954.8k | 316,121 | | Reduced −71,271 | | [Divisadero Street Capital Management, LP](/funds/1901865.md) | 2026-06-30 | $841.0k | 278,485 | | Reduced −7,593 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $731.8k | 242,334 | | Reduced −9,900 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $465.7k | 154,152 | | Reduced −11,398 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $460.8k | 152,573 | | Reduced −20,297 | | [Sachetta, LLC](/funds/2010574.md) | 2026-06-30 | $459.1k | 152,008 | | Added +1,500 | | [Greenline Wealth Management LLC](/funds/2111541.md) | 2026-06-30 | $388.9k | 128,774 | | Unchanged | | [North Star Investment Management Corp.](/funds/1342857.md) | 2026-06-30 | $379.3k | 125,586 | | Unchanged | ## Recent filings [All 407 filings](/companies/srts/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 11:55 ET | [10-Q](/filings/0001753926-26-001508.md) | Quarterly report, period 2026-06-30 | 0001753926-26-001508 | | 2026-08-13 | 16:13 ET | [8-K](/filings/0001753926-26-001479.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001753926-26-001479 | | 2026-06-05 | 16:08 ET | [8-K](/filings/0001753926-26-000983.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001753926-26-000983 | | 2026-06-02 | 08:26 ET | [8-K](/filings/0001753926-26-000960.md) | 5.07 Shareholder vote results | 0001753926-26-000960 | | 2026-05-13 | 14:48 ET | [10-Q](/filings/0001753926-26-000845.md) | Quarterly report, period 2026-03-31 | 0001753926-26-000845 | | 2026-05-07 | 16:14 ET | [8-K](/filings/0001753926-26-000782.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001753926-26-000782 | | 2026-04-29 | 16:11 ET | [DEF 14A](/filings/0001753926-26-000749.md) | Proxy statement, period 2026-05-29 | 0001753926-26-000749 | | 2026-03-04 | 12:15 ET | [10-K](/filings/0001753926-26-000435.md) | Annual report, period 2025-12-31 | 0001753926-26-000435 | | 2026-02-12 | 16:09 ET | [8-K](/filings/0001753926-26-000315.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001753926-26-000315 | | 2026-01-20 | 11:07 ET | [8-K](/filings/0001753926-26-000147.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001753926-26-000147 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001753926-26-000435.md), filed Mar 4, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d97a7fa8-8e8e-4b08-8483-c3cc2a4aea67) ## About the filer - CIK: 1494891 - Tickers: SRTS - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.